Ontology highlight
ABSTRACT:
SUBMITTER: Kaley T
PROVIDER: S-EPMC6286161 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Kaley Thomas T Touat Mehdi M Subbiah Vivek V Hollebecque Antoine A Rodon Jordi J Lockhart A Craig AC Keedy Vicki V Bielle Franck F Hofheinz Ralf-Dieter RD Joly Florence F Blay Jean-Yves JY Chau Ian I Puzanov Igor I Raje Noopur S NS Wolf Jurgen J DeAngelis Lisa M LM Makrutzki Martina M Riehl Todd T Pitcher Bethany B Baselga Jose J Hyman David M DM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20181023 35
<h4>Purpose</h4><i>BRAF</i><sup>V600</sup> mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of <i>BRAF</i><sup>V600</sup>, in patients with gliomas that harbor this mutation.<h4>Patients and methods</h4>The VE-BASKET study was an open-label, nonrandomized, multicohort study for <i>BRAF</i><sup>V600</sup>-mutant ...[more]